{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:18:36Z","timestamp":1791512316501,"version":"4.3.4"},"reference-count":69,"publisher":"American Chemical Society (ACS)","issue":"1","license":[{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ACS Infect. Dis."],"published-print":{"date-parts":[[2020,1,10]]},"DOI":"10.1021\/acsinfecdis.9b00178","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T08:24:37Z","timestamp":1571300677000},"page":"64-73","source":"Crossref","is-referenced-by-count":35,"title":["Rational Design of Doravirine: From Bench to Patients"],"prefix":"10.1021","volume":"6","author":[{"given":"Carey","family":"Hwang","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey 07033, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Tain","family":"Lai","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey 07033, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6894-1056","authenticated-orcid":true,"given":"Daria","family":"Hazuda","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey 07033, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"key":"ref1\/cit1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2005.05.001"},{"issue":"1","key":"ref2\/cit2","first-page":"29","volume":"8","author":"Singh R.","year":"2017","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"ref3\/cit3","unstructured":"Boehringer Ingelheim Pharmaceuticals,\nInc. (2018)\n                      VIRAMUNE\n(nevirapine): prescribing information\n                      , Ridgefield, CT."},{"key":"ref4\/cit4","unstructured":"Delavirdine\ngets FDA approval. Food and Drug Administration.\n                      AIDS Alert\n                      1997, 12 (6), 70."},{"key":"ref5\/cit5","unstructured":"Bristol-Myers\nSquibb Company. (2017)\n                      SUSTIVA (efavirenz): prescribing information\n                      , Princeton,\nNJ."},{"key":"ref6\/cit6","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a007161"},{"key":"ref7\/cit7","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181a56e81"},{"key":"ref8\/cit8","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M359"},{"key":"ref9\/cit9","unstructured":"Janssen Therapeutics. (2019)\n                      INTELENCE (etravirine): prescribing\ninformation\n                      , Titusville, NJ."},{"key":"ref10\/cit10","unstructured":"Janssen Therapeutics. (2019)\n                      EDURANT (rilpivirine): prescribing information\n                      , Titusville,\nNJ."},{"key":"ref11\/cit11","unstructured":"U.S. Department of Health and\nHuman Services, AIDSinfo. (2019) FDA-approved HIV medicines. https:\/\/aidsinfo.nih.gov\/understanding-hiv-aids\/fact-sheets\/21\/58\/fda-approved-hiv-medicines (accessed Sept 5, 2019)."},{"key":"ref12\/cit12","unstructured":"Merck &\nCo., Inc. (2019)\n                      DELSTRIGO\n(doravirine, lamivudine, and tenoovir disoproxil\nfumarate): prescribing information\n                      , Whitehouse Station, NJ."},{"key":"ref13\/cit13","unstructured":"Merck & Co., Inc. (2019)\n                      PIFELTRO (doravirine): prescribing information\n                      , Whitehouse Station, NJ."},{"key":"ref14\/cit14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.6390"},{"key":"ref15\/cit15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8900"},{"key":"ref16\/cit16","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation\nand Research. (2015) Human immunodeficiency virus-1 infection: developing antiretroviral\ndrugs for treatment. Guidance for industry. www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm355128.pdf (accessed May 18, 2019)."},{"key":"ref17\/cit17","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-9-99"},{"key":"ref18\/cit18","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2014.863708"},{"key":"ref19\/cit19","unstructured":"Gilead Sciences, Inc. (2018)\n                      COMPLERA (emtricitabine, rilpivirine,\ntenofovir disoproxil\nfumarate): prescribing information\n                      , Foster City, CA."},{"key":"ref20\/cit20","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31823df4da"},{"key":"ref21\/cit21","volume-title":"NEJM Journal Watch","author":"Sax P. E.","year":"2015"},{"key":"ref22\/cit22","unstructured":"Panel on Antiretroviral\nGuidelines for Adults and Adolescents. (2019)\n                      Guidelines for the Use\nof Antiretroviral Agents in Adults and Adolescents Living with HIV\n                      . http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf (accessed July 13, 2019)."},{"key":"ref23\/cit23","unstructured":"Gilead Sciences,\nInc. (2019)\n                      BIKTARVY\n(bictegravir, emtricitabine, and tenofovir alafenamide):\nprescribing information\n                      , Foster City, CA."},{"key":"ref24\/cit24","unstructured":"Merck & Co., Inc. (2019)\n                      ISENTRESS (raltegravir): prescribing information\n                      , Whitehouse Station, NJ."},{"key":"ref25\/cit25","unstructured":"GlaxoSmithKline. (2019)\n                      TIVICAY (dolutegravir):\nprescribing information\n                      , Research Triangle Park, NC."},{"key":"ref26\/cit26","volume-title":"VITEKTA (elvitegravir): prescribing information","author":"Gilead Sciences, Inc.","year":"2015"},{"key":"ref27\/cit27","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(98)00025-4"},{"key":"ref28\/cit28","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.200490012"},{"key":"ref29\/cit29","doi-asserted-by":"publisher","DOI":"10.1126\/science.1377403"},{"key":"ref30\/cit30","doi-asserted-by":"publisher","DOI":"10.2174\/1570162043351093"},{"key":"ref31\/cit31","doi-asserted-by":"publisher","DOI":"10.1126\/science.7532321"},{"key":"ref32\/cit32","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1994.1665"},{"key":"ref33\/cit33","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku819"},{"key":"ref34\/cit34","doi-asserted-by":"publisher","DOI":"10.1021\/jm040840e"},{"key":"ref35\/cit35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711209105"},{"key":"ref36\/cit36","doi-asserted-by":"publisher","DOI":"10.1021\/jm030558s"},{"key":"ref37\/cit37","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02403-13"},{"key":"ref38\/cit38","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00591-12"},{"key":"ref39\/cit39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.03.064"},{"key":"ref40\/cit40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.12.070"},{"key":"ref41\/cit41","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000471"},{"key":"ref42\/cit42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02650-15"},{"key":"ref43\/cit43","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04201-14"},{"key":"ref44\/cit44","doi-asserted-by":"publisher","DOI":"10.1021\/jm2010173"},{"key":"ref45\/cit45","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01559-08"},{"key":"ref46\/cit46","unstructured":"Lai, M. T., Sachs, N., Feng, M., Grobler, J., Blair, W., Miller, M., and Hazuda, D. J. (2016) Suppress NNRTI-resistant mutants by doravirine at clinically relevant concentrations. Presented at the Conference on Retroviruses and Opportunistic Infections, Boston, MA, Feb 22\u221225, 2016, Abstract 506."},{"key":"ref47\/cit47","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy540"},{"key":"ref48\/cit48","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30021-3"},{"key":"ref49\/cit49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001810"},{"key":"ref51\/cit51","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2920"},{"key":"ref52\/cit52","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3142"},{"key":"ref53\/cit53","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000842"},{"issue":"9","key":"ref54\/cit54","first-page":"311","volume":"105","author":"Briggs R.","year":"2012","journal-title":"Ir. Med. J."},{"key":"ref55\/cit55","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2018.1451667"},{"key":"ref56\/cit56","doi-asserted-by":"publisher","DOI":"10.1310\/hct1405-216"},{"key":"ref57\/cit57","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.156"},{"key":"ref58\/cit58","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2009.0302"},{"key":"ref59\/cit59","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832d7350"},{"key":"ref60\/cit60","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01364-16"},{"key":"ref61\/cit61","unstructured":"Khalilieh, S., Yee, K. L., Sanchez, R. I., Vaynshteyn, K., Deschamps, K., Fan, L., Martell, M., Jordan, H., and Iwamoto, M. (2017) Co-administration of doravirine with an aluminum\/magnesium-containing antacid or pantoprazole, a proton-pump inhibitor, does not have a clinically meaningful effect on doravirine pharmacokinetics. Presented at the 9th International AIDS Society (IAS) Conference on HIV Science, Paris, France, July 23\u221226, 2017, Abstract MOPEB0334."},{"key":"ref62\/cit62","unstructured":"Anderson, M. S., Kaufman, D., Castronuovo, P., Tetteh, E., Yee, K. L., Liu, Y., Fan, L., Armas, D., Wagner, J. A., and Butterton, J. R. (2016) Effect of doravirine (MK-1439) on the pharmacokinetics of oral contraceptive (ethinyl estradiol [EE] and levonorgestrol [LNG]). Presented at the 6th International Workshop on HIV & Women, Boston, MA, Feb 20\u221221, 2016."},{"key":"ref63\/cit63","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0512-5"},{"key":"ref64\/cit64","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12488"},{"key":"ref65\/cit65","doi-asserted-by":"publisher","DOI":"10.1086\/380791"},{"key":"ref66\/cit66","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12196"},{"key":"ref67\/cit67","unstructured":"Tannenbaum, P., Binns, J., Tye, S., Savitz, A., Fox, S., Burgey, C., Lai, M. T., Simen, A., Hazuda, D., and Miller, M. D. (2015) Quantitative electroencephalogram as a translational biomarker for NNRTI CNS AEs. Presented at the 22nd Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Feb 23\u221226, 2015, Abstract 449."},{"key":"ref68\/cit68","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0552-x"},{"key":"ref69\/cit69","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60983-5"},{"key":"ref70\/cit70","doi-asserted-by":"crossref","unstructured":"Kumar, P., Johnson, M., Molina, J. M., Rizzardini, G., Cahn, P., Bickel, M., Mallolas, J., Zhou, Y., Morais, C., Kumar, S., Sklar, P., Hanna, G. J., Hwang, C., and Greaves, W., for the DRIVE-SHIFT Study Group. (2018) Switch to doravirine\/lamivudine\/tenofovir disoproxil fumarate (DOR\/3TC\/TDF) maintains virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial. Presented at IDWeek 2018, San Francisco, CA, Oct 3\u22127, 2018, Abstract LB2.","DOI":"10.1093\/ofid\/ofy229.2176"}],"container-title":["ACS Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsinfecdis.9b00178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T16:26:43Z","timestamp":1681576003000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acsinfecdis.9b00178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,17]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,10]]}},"alternative-id":["10.1021\/acsinfecdis.9b00178"],"URL":"https:\/\/doi.org\/10.1021\/acsinfecdis.9b00178","relation":{},"ISSN":["2373-8227","2373-8227"],"issn-type":[{"value":"2373-8227","type":"print"},{"value":"2373-8227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,17]]}}}